• Explore /
  • Poster
  • / Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

Abstract Video & Slides Poster

Authors

null

Joaquim Bellmunt

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Joaquim Bellmunt , Andrea Necchi , Ronald De Wit , Jae-Lyun Lee , Lawrence Fong , Nicholas J. Vogelzang , Miguel A. Climent Durán , Daniel P. Petrylak , Toni K. Choueiri , Winald R. Gerritsen , Howard Gurney , David I. Quinn , Stephane Culine , Cora N. Sternberg , Jin Zhi Xu , Blanca Homet Moreno , James Luke Godwin , Dean F. Bajorin , David J. Vaughn , Yves Fradet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02256436

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4532)

DOI

10.1200/JCO.2021.39.15_suppl.4532

Abstract #

4532

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Yves Fradet

First Author: Joaquim Bellmunt

First Author: Thomas Powles

First Author: Ronald De Wit